<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00454181</url>
  </required_header>
  <id_info>
    <org_study_id>03HUHI19</org_study_id>
    <nct_id>NCT00454181</nct_id>
  </id_info>
  <brief_title>Treatment of Oral Warts in HIV+ Patients</brief_title>
  <official_title>Evaluation of Natural Human Interferon Alpha Administered Oromucosally in the Treatment of Oral Warts in HIV-seropositive Subjects Receiving Combination Anti-retroviral Therapy: A Phase 2 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amarillo Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amarillo Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to test lozenges of interferon-alpha that are dissolved in the mouth as a
      treatment of oral warts in HIV-positive adults.

      The hypothesis of this study is that interferon-alpha will be safe and that a higher
      percentage of subjects given interferon-alpha will experience a complete or nearly complete
      remission of their oral warts compared to subjects given placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human papilloma virus (HPV) can cause warts to form in the mouth of infected patients,
      particularly those with reduced immunity such as people infected with HIV. This is a
      randomized, double-blind, placebo-controlled trial to determine whether interferon-alpha,
      delivered in low doses via orally dissolving lozenges, can reduce or eliminate these warts in
      HIV+ subjects who are receiving combination anti-retroviral therapy (HAART). All potential
      subjects will have their warts examined and measured at a screening visit. A small amount of
      one wart (i.e. a biopsy) will be removed for microscopic evaluation to confirm HPV infection
      and a small amount of blood will be collected for testing. Subjects that qualify for entry
      will return for a baseline visit at which they will be randomized to active or placebo
      treatment for 24 weeks. Three out of four subjects will receive active treatment in this
      study. Subjects must return to the clinic every 6 weeks during treatment to have their warts
      re-examined. At these follow-up visits, subjects will be asked to complete a brief
      questionnaire regarding any perceived changes in their warts and their overall mouth
      condition. A small amount of blood will be taken at the final study visit at week 24 to
      assess the safety of the interferon lozenges.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Oral Mucosal Area Covered by Warts.</measure>
    <time_frame>24 weeks, from baseline to the end of treatment</time_frame>
    <description>Number of subjects with a 75% or greater decrease from baseline to week 24 in total oral wart area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Surface Area of the Lips Covered by Warts</measure>
    <time_frame>24 weeks, from baseline to the end of treatment</time_frame>
    <description>Number of subjects with a 75% or greater decrease from baseline to week 24 in total lip wart area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Questionnaire Regarding Changes in Warts</measure>
    <time_frame>24 weeks, from baseline to the end of treatment</time_frame>
    <description>Number of subjects reporting change in oral warts from baseline to week 24 as &quot;better.&quot; Scale was subjective with 3 choices: &quot;better,&quot; &quot;worse,&quot; or &quot;unchanged.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Questionnaire Regarding Global Oral Changes</measure>
    <time_frame>24 weeks, from baseline to end of treatment</time_frame>
    <description>Number of subjects reporting change in global oral health from baseline to week 24 as &quot;better.&quot; Scale was subjective with 3 choices: &quot;better,&quot; &quot;worse,&quot; or &quot;unchanged.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment Regarding Changes in Warts</measure>
    <time_frame>24 weeks, from baseline to the end of treatment</time_frame>
    <description>Number of subjects with improvement in oral warts from baseline to week 24 as rated by the attending investigator. Scale was subjective with 3 choices: &quot;improved,&quot; &quot;worsened,&quot; or &quot;unchanged.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment Regarding Global Oral Changes.</measure>
    <time_frame>24 weeks, from baseline to the end of treatment</time_frame>
    <description>Number of subjects with improvement from baseline to week 24 in global oral health as rated by the attending investigator. Scale was subjective with 3 choices: &quot;improved,&quot; &quot;worsened,&quot; or &quot;unchanged.&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Papillomatosis</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>IFN lozenges</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 IU Interferon-alpha lozenges for oral dissolution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo lozenges</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>200 mg lozenges containing anhydrous crystalline maltose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-alpha</intervention_name>
    <description>500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks</description>
    <arm_group_label>IFN lozenges</arm_group_label>
    <other_name>Veldona</other_name>
    <other_name>IFN-alpha lozenge</other_name>
    <other_name>low dose IFN lozenge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>200 mg lozenges containing anhydrous crystalline maltose taken three times per day for 24 weeks</description>
    <arm_group_label>placebo lozenges</arm_group_label>
    <other_name>maltose</other_name>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have tested positive for HIV.

          -  Must have two or more warts inside the mouth.

          -  Must be receiving a standard course of anti-retroviral therapy (HAART).

        Exclusion Criteria:

          -  Must not be receiving oral or injected steroids.

          -  Must not be taking other drugs for treatment of oral warts.

          -  Must not have other active HIV-related opportunistic infections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Greenspan, BDS, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, School of Dentistry</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Southeastern University College of Dental Medicine</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33328-2018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia School of Dentistry</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912-1241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago, College of Dentistry</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky College of Dentistry</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0297</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Baltimore Dental School</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Oral Medicine and Dentistry, Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ - New Jersey Dental School</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University College of Dentistry</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania School of Dental Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Dentistry</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2007</study_first_submitted>
  <study_first_submitted_qc>March 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2007</study_first_posted>
  <results_first_submitted>November 9, 2010</results_first_submitted>
  <results_first_submitted_qc>December 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2011</results_first_posted>
  <last_update_submitted>September 12, 2011</last_update_submitted>
  <last_update_submitted_qc>September 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>human immunodeficiency virus</keyword>
  <keyword>human papilloma virus</keyword>
  <keyword>warts, oral</keyword>
  <keyword>papillomatosis</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment took place between January 2007 and March 2009 at 10 university-affiliated dental clinics across the US.</recruitment_details>
      <pre_assignment_details>All 59 enrolled subjects were randomized to treatment and took at least 1 dose of assigned study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IFN Lozenges</title>
          <description>500 IU Interferon-alpha lozenges for oral dissolution</description>
        </group>
        <group group_id="P2">
          <title>Placebo Lozenges</title>
          <description>200 mg lozenges containing anhydrous crystalline maltose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IFN Lozenges</title>
          <description>500 IU Interferon-alpha lozenges for oral dissolution</description>
        </group>
        <group group_id="B2">
          <title>Placebo Lozenges</title>
          <description>200 mg lozenges containing anhydrous crystalline maltose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.0" spread="5.05"/>
                    <measurement group_id="B2" value="46.6" spread="5.43"/>
                    <measurement group_id="B3" value="45.4" spread="5.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Total Oral Mucosal Area Covered by Warts.</title>
        <description>Number of subjects with a 75% or greater decrease from baseline to week 24 in total oral wart area</description>
        <time_frame>24 weeks, from baseline to the end of treatment</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>IFN Lozenges</title>
            <description>500 IU Interferon-alpha lozenges for oral dissolution</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenges</title>
            <description>200 mg lozenges containing anhydrous crystalline maltose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Oral Mucosal Area Covered by Warts.</title>
          <description>Number of subjects with a 75% or greater decrease from baseline to week 24 in total oral wart area</description>
          <population>Per protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chi-square analysis of the proportion of subjects in each group meeting the definition of positive response.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Surface Area of the Lips Covered by Warts</title>
        <description>Number of subjects with a 75% or greater decrease from baseline to week 24 in total lip wart area</description>
        <time_frame>24 weeks, from baseline to the end of treatment</time_frame>
        <population>Per protocol - only a sub-set of subjects had lip warts at study entry</population>
        <group_list>
          <group group_id="O1">
            <title>IFN Lozenges</title>
            <description>500 IU Interferon-alpha lozenges for oral dissolution</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenges</title>
            <description>200 mg lozenges containing anhydrous crystalline maltose</description>
          </group>
        </group_list>
        <measure>
          <title>Total Surface Area of the Lips Covered by Warts</title>
          <description>Number of subjects with a 75% or greater decrease from baseline to week 24 in total lip wart area</description>
          <population>Per protocol - only a sub-set of subjects had lip warts at study entry</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chi-square analysis of the proportion of subjects in each group meeting the definition of positive response</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Questionnaire Regarding Changes in Warts</title>
        <description>Number of subjects reporting change in oral warts from baseline to week 24 as &quot;better.&quot; Scale was subjective with 3 choices: &quot;better,&quot; &quot;worse,&quot; or &quot;unchanged.&quot;</description>
        <time_frame>24 weeks, from baseline to the end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IFN Lozenges</title>
            <description>500 IU Interferon-alpha lozenges for oral dissolution</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenges</title>
            <description>200 mg lozenges containing anhydrous crystalline maltose</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Questionnaire Regarding Changes in Warts</title>
          <description>Number of subjects reporting change in oral warts from baseline to week 24 as &quot;better.&quot; Scale was subjective with 3 choices: &quot;better,&quot; &quot;worse,&quot; or &quot;unchanged.&quot;</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chi-square analysis of the proportion of subjects in each group reporting change in oral warts from baseline to week 24 as &quot;better.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Questionnaire Regarding Global Oral Changes</title>
        <description>Number of subjects reporting change in global oral health from baseline to week 24 as &quot;better.&quot; Scale was subjective with 3 choices: &quot;better,&quot; &quot;worse,&quot; or &quot;unchanged.&quot;</description>
        <time_frame>24 weeks, from baseline to end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IFN Lozenges</title>
            <description>500 IU Interferon-alpha lozenges for oral dissolution</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenges</title>
            <description>200 mg lozenges containing anhydrous crystalline maltose</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Questionnaire Regarding Global Oral Changes</title>
          <description>Number of subjects reporting change in global oral health from baseline to week 24 as &quot;better.&quot; Scale was subjective with 3 choices: &quot;better,&quot; &quot;worse,&quot; or &quot;unchanged.&quot;</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chi-square analysis of the proportion of subjects in each group reporting change in global oral health from baseline to week 24 as &quot;better.&quot;</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Assessment Regarding Changes in Warts</title>
        <description>Number of subjects with improvement in oral warts from baseline to week 24 as rated by the attending investigator. Scale was subjective with 3 choices: &quot;improved,&quot; &quot;worsened,&quot; or &quot;unchanged.&quot;</description>
        <time_frame>24 weeks, from baseline to the end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IFN Lozenges</title>
            <description>500 IU Interferon-alpha lozenges for oral dissolution</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenges</title>
            <description>200 mg lozenges containing anhydrous crystalline maltose</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Assessment Regarding Changes in Warts</title>
          <description>Number of subjects with improvement in oral warts from baseline to week 24 as rated by the attending investigator. Scale was subjective with 3 choices: &quot;improved,&quot; &quot;worsened,&quot; or &quot;unchanged.&quot;</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chi-square analysis of the proportion of subjects rated as &quot;improved&quot; with respect to changes in oral warts from baseline to week 24 by the attending investigator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Assessment Regarding Global Oral Changes.</title>
        <description>Number of subjects with improvement from baseline to week 24 in global oral health as rated by the attending investigator. Scale was subjective with 3 choices: &quot;improved,&quot; &quot;worsened,&quot; or &quot;unchanged.&quot;</description>
        <time_frame>24 weeks, from baseline to the end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IFN Lozenges</title>
            <description>500 IU Interferon-alpha lozenges for oral dissolution</description>
          </group>
          <group group_id="O2">
            <title>Placebo Lozenges</title>
            <description>200 mg lozenges containing anhydrous crystalline maltose</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Assessment Regarding Global Oral Changes.</title>
          <description>Number of subjects with improvement from baseline to week 24 in global oral health as rated by the attending investigator. Scale was subjective with 3 choices: &quot;improved,&quot; &quot;worsened,&quot; or &quot;unchanged.&quot;</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Chi-square analysis of the proportion of subjects rated as &quot;improved&quot; with resepect to changes from baseline to week 24 in global oral health by the attending investigator.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.71</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IFN Lozenges</title>
          <description>500 IU Interferon-alpha lozenges for oral dissolution</description>
        </group>
        <group group_id="E2">
          <title>Placebo Lozenges</title>
          <description>200 mg lozenges containing anhydrous crystalline maltose</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>esophageal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>anal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>candidiasis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>tooth extraction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only 59 of 80 planned subjects were randomized, so statistical power of the study was limited.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Martin J. Cummins</name_or_title>
      <organization>Amarillo Biosciences, Inc.</organization>
      <phone>806-376-1741 ext 14</phone>
      <email>mcummins@amarbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

